Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/FOXO TECHNOLOGIES INC./ 8-K

Current Report · Items 1.01, 9.01 · 8-K

FOXO TECHNOLOGIES INC.

FOXOOTCEQUITYCurrent

Entry into a Material Definitive Agreement

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 2.1 Asset Purchase Agreement, dated July 22, 2026, by and between Vector BioSource, Inc.…

Filed Jul 27, 2026Accepted Jul 27, 2026, 4:05 PM EDTCIK 1812360Accession 0001493152-26-034793
View company →Permanent SEC source ↗
Share

Company context

We are a healthcare services and technology company operating in three reportable business segments: (i) Healthcare, (ii) Life Science Services and (iii) Labs, formerly referred to as Labs and Life. These segments further operate in four synergistic divisions, a rural hospital division and a mental and behavioral health division, which make up our Healthcare segment, a biospecimens division, which makes up our Life Science Services segment and an epigenetics diagnostics and interpretation division, which makes up our Labs segment. Our rural hospital division, biospecimens division and epigenetics diagnostics and interpretation division operate through wholly owned subsidiaries, and our behavioral health division operates through a majority-owned subsidiary.

Current securities

FOXOOTC · EQUITY · CurrentFOXOWOTC · WARRANT · Current
Historical securities (5)
DWINOTC · EQUITY · Historical · closed Sep 15, 2022DWIN.UNNYSE · UNIT · Historical · closed Sep 15, 2022DWIN.WSNYSE · WARRANT · Historical · closed Sep 15, 2022FOXOWOTC · WARRANT · Historical · closed May 17, 2023FOXO.WSNYSE · WARRANT · Historical · closed Jan 24, 2023

Recent company filings

  1. DEF 14C filingAug 24, 2026
  2. PRE 14C filingAug 14, 2026
  3. 10-Q filingAug 14, 2026
  4. Submission of Matters to a Vote of Security HoldersAug 14, 2026
  5. Regulation FD DisclosureJul 29, 2026

Disclosure sections

Items 1.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 2.1 Asset Purchase Agreement, dated July 22, 2026, by and between Vector BioSource, Inc. and Grifols Bio Supplies, Inc.* 104 Cover Page Interactive Data File (formatted in Inline XBRL) *Certain schedules and exhibits omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.